169 related articles for article (PubMed ID: 32725772)
21. The association between low skeletal muscle mass and low skeletal muscle radiodensity with functional impairment, systemic inflammation, and reduced survival in patients with incurable cancer.
Calixto-Lima L; Wiegert EVM; Oliveira LC; Chaves GV; Bezerra FF; Avesani CM
JPEN J Parenter Enteral Nutr; 2023 Feb; 47(2):265-275. PubMed ID: 36325962
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
24. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study.
Sas-Korczyńska B; Łuczyńska E; Kamzol W; Sokołowski A
Strahlenther Onkol; 2017 Feb; 193(2):141-149. PubMed ID: 27785518
[TBL] [Abstract][Full Text] [Related]
25. Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
Halvorsen TO; Herje M; Levin N; Bremnes RM; Brustugun OT; Fløtten Ø; Kaasa S; Sundstrøm S; Grønberg BH
Lung Cancer; 2016 Dec; 102():9-14. PubMed ID: 27987595
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer.
Xia B; Hong LZ; Cai XW; Zhu ZF; Liu Q; Zhao KL; Fan M; Mao JF; Yang HJ; Wu KL; Fu XL
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):517-23. PubMed ID: 25481679
[TBL] [Abstract][Full Text] [Related]
27. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
Suzuki R; Wei X; Allen PK; Welsh JW; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2018 Nov; 19(6):e885-e891. PubMed ID: 30197263
[TBL] [Abstract][Full Text] [Related]
28. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.
Huang X; Lv LN; Zhao Y; Li L; Zhu XD
Clin Nutr; 2021 Jan; 40(1):295-302. PubMed ID: 32507513
[TBL] [Abstract][Full Text] [Related]
29. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Hu X; Bao Y; Xu YJ; Zhu HN; Liu JS; Zhang L; Guo Y; Jin Y; Wang J; Ma HL; Xu XL; Song ZB; Tang HR; Peng F; Fang M; Kong Y; Chen MY; Dong BQ; Zhu L; Yu C; Yu XM; Hong W; Fan Y; Zhang YP; Chen PC; Zhao Q; Jiang YH; Zhou XM; Chen QX; Sun WY; Mao WM; Chen M
Cancer; 2020 Feb; 126(4):840-849. PubMed ID: 31714592
[TBL] [Abstract][Full Text] [Related]
30. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
Johnson DH; Turrisi AT; Chang AY; Blum R; Bonomi P; Ettinger D; Wagner H
J Clin Oncol; 1993 May; 11(5):879-84. PubMed ID: 8387577
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
32. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Salama JK; Pang H; Bogart JA; Blackstock AW; Urbanic JJ; Hogson L; Crawford J; Vokes EE
Lung Cancer; 2013 Dec; 82(3):436-40. PubMed ID: 24396884
[TBL] [Abstract][Full Text] [Related]
33. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
34. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
35. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
36. Muscle mass and association to quality of life in non-small cell lung cancer patients.
Bye A; Sjøblom B; Wentzel-Larsen T; Grønberg BH; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Jordhøy M
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):759-767. PubMed ID: 28493418
[TBL] [Abstract][Full Text] [Related]
37. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
38. Mid-course thoracic radiotherapy with cisplatin-etoposide chemotherapy in limited-stage small-cell lung cancer.
Akyurek S; Onal C; Cagar A; Hicsonmez A; Andrieu MN; Kurtman C
Med Oncol; 2006; 23(4):499-505. PubMed ID: 17303908
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer.
Sun JM; Ahn YC; Choi EK; Ahn MJ; Ahn JS; Lee SH; Lee DH; Pyo H; Song SY; Jung SH; Jo JS; Jo J; Sohn HJ; Suh C; Lee JS; Kim SW; Park K
Ann Oncol; 2013 Aug; 24(8):2088-92. PubMed ID: 23592701
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
